Amphivena Therapeutics
South San Francisco
About Amphivena Therapeutics
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, and enhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing. It was founded in 2012 and is headquartered in South San Francisco, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $135.7M
- Funding stage: Late Stage Venture
- Last round: Series C (Sep 2019)
- Website: amphivena.com
- Phone: 415-994-6455
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/amphivena-therapeutics-32173 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.